Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial

Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial

The final analysis of the phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) trial showed improvement in overall survival (OS) and other efficacy endpoints with apalutamide plus androgen deprivation therapy (ADT) versus ADT alone in patients with metastatic castration...

Full description

Bibliographic Details
Main Authors: Byung Ha Chung, Jian Huang, Hiroji Uemura, Young Deuk Choi, Zhang-Qun Ye, Hiroyoshi Suzuki, Taek Won Kang, Da-Lin He, Jae Young Joung, Sabine D Brookman-May, Sharon McCarthy, Amitabha Bhaumik, Anildeep Singh, Suneel Mundle, Simon Chowdhury, Neeraj Agarwal, Ding-Wei Ye, Kim N Chi, Hirotsugu Uemura
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Asian Journal of Andrology
Subjects:
apalutamide; asia; event-driven analysis; metastatic castration-sensitive prostate cancer; overall survival
Online Access:http://www.ajandrology.com/article.asp?issn=1008-682X;year=2023;volume=25;issue=6;spage=653;epage=661;aulast=

Internet

http://www.ajandrology.com/article.asp?issn=1008-682X;year=2023;volume=25;issue=6;spage=653;epage=661;aulast=

Similar Items